Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.
Animal Pharmaceuticals
Powder
Veterinary Grade
68786-66-3
359.7 g/mol Grams (g)
WHITE POWDER
C14H9Cl3N2OS
antihelminthic
Trade Information
MUMBAI
1000 Kilograms Per Month
2-3 Days
All India
Product Description
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. Fascioliasis is a parasitic infection often caused by the helminth, Fasciola hepatica, which is also known as âÂÂthe common liver flukeâ or âÂÂthe sheep liver flukeâ or by Fasciola gigantica, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.
HINDUSTAN CHEMICALS AND PHARMACEUTICALS
Other Products in 'Veterinary Ingredients' category